Navigation Links
Novavax Reports First Quarter 2009 Financial Results
Date:5/8/2009

ROCKVILLE, Md., May 8 /PRNewswire-FirstCall/ - Novavax Inc. (Nasdaq: NVAX) today announced financial results for the first quarter of 2009. Novavax reported a net loss of $8.3 million, or $0.12 per share, for the first quarter of 2009 compared to a net loss of $7.8 million, or $0.13 per share, for the first quarter of 2008. The Company spent a total of $7.4 million in the first quarter of 2009 and ended the quarter with $25.6 million in cash and short-term investments. During the quarter, the Company made significant progress in developing its vaccine pipeline, improved its balance sheet by raising capital and retiring a majority of its convertible debt, and completed a transaction with Cadila Pharmaceutical Limited to create a Joint Venture Company in India.

Specifically accomplishments since the 2008 year end financial results include the following:

  • Commenced development of a VLP vaccine candidate against the novel influenza A (H1N1) virus that has recently emerged in the United States and Mexico.
  • Publication of results in the Journal of Virology from preclinical studies conducted under a collaborative research and development agreement (CRADA) between the Centers for Disease Control and Prevention (CDC) and Novavax showing that an investigational H1N1 VLP vaccine based on the 1918 Spanish influenza strain protected against both the Spanish flu and a highly pathogenic H5N1 avian influenza strain.
  • Announced the initiation of enrollment in the second Phase II study of its trivalent seasonal influenza VLP vaccine candidate. This clinical trial is designed to evaluate the safety and immunogenicity of a broader range of vaccine doses and to provide data to help select doses for future studies in older adults and a Phase III efficacy study. The Company plans to report top-line immunogenicity and safety results from this study by the fourth quarte
    '/>"/>

SOURCE Novavax, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Novavax Announces Enrollment in the Second Phase II Study of its Seasonal Influenza VLP Vaccine Candidate
2. Novavax Announces Release Date of 2009 First Quarter, Financial Results and Investor Conference Call
3. Novavax Announces Early Retirement of $17 Million of Convertible Debt
4. NOVAVAX Announces Publication of a Preclinical Study Demonstrating that a Virus-like Particle Vaccine Provided Protection Against Highly Pathogenic H1N1 and H5N1 Influenza Strains
5. Novavax Announces New Capital Infusion Through a Strategic Alliance with Cadila Pharmaceuticals of India
6. Novavax Announces New Release Date of 2008 Fourth Quarter Financial Results and Investor Conference Call
7. Novavax Announces Release Date of 2008 Fourth Quarter Financial Results and Investor Conference Call
8. Novavax to Present at Cowen and Company 29th Annual Healthcare Conference
9. NOVAVAX Announces Preclinical Study Results for a Respiratory Syncytial Virus (RSV) Vaccine Candidate Directed Against the Fusion (F) Protein
10. Novavax and Vivalis Sign a Research License Agreement to Use the EB66(R) Cell Line for the Production of Virus Like Particle Based Vaccines
11. Novavax Announces Operational Status of Its Vaccine Pilot Plant and Commercial Launch Facility
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... BOSTON, MA (PRWEB) October 30, 2014 ... communication and collaboration provider, offers Office 365 end ... software into a complete phone system by adding ... Office 365 (O365) includes Lync Online, a communication ... to Lync calls. With hosted voice, O365 becomes ...
(Date:10/30/2014)... October 30, 2014 Spartan Bioscience announced ... RX CYP2C19 System . It detects CYP2C19 genetic mutations ... swab. , The Spartan RX CYP2C19 System is the ... been approved in Canada. Due to the system’s ease ... be used by healthcare professionals such as doctors, nurses, ...
(Date:10/30/2014)... Al Khaimah, UAE (PRWEB) October 30, 2014 ... appointment of Dr. James A. Manganello, Chairman of the Board, ... of The Bahamas. The appointment was made by the ... Bahamas on September 24th, 2014. , More than ... Therapy and Research Bill , Prime Minister Perry Christie said ...
(Date:10/30/2014)... N.J. , Oct. 30, 2014  Regado Biosciences, ... it will hold a conference call and live audio ... EST to discuss its third quarter 2014 financial results. ... conference call by dialing (888) 347-1165 for domestic callers ... will be webcast live under the investor relations section ...
Breaking Biology Technology:SoundConnect Launches Voice Enablement and Hybrid Audio Conferencing for Office 365 2SoundConnect Launches Voice Enablement and Hybrid Audio Conferencing for Office 365 3Health Canada approves first near-patient DNA test for personalized medicine 2Health Canada approves first near-patient DNA test for personalized medicine 3Grace Century’s Stem Cell Biobank Project Announces Chairman’s Appointment to National Stem Cell Ethics Committee of The Bahamas 2Grace Century’s Stem Cell Biobank Project Announces Chairman’s Appointment to National Stem Cell Ethics Committee of The Bahamas 3Regado Biosciences to Provide Third Quarter 2014 Financial Results 2
... NBIX ) today announced its financial results for the ... the fourth quarter of 2010, the Company reported net income of ... loss of $7.9 million, or $0.20 per basic share, for the ... the Company reported a net loss of $8.0 million, or $0.15 ...
... Technologies, Inc., a privately-held orthobiologics company, announced today that ... is scheduled to present at Canaccord Genuity,s Musculoskeletal Conference ... February 15, 2011 at 10:00 AM (PT).  The conference, ... Meeting, will feature presentations from over 60 public and ...
... Mass., Feb. 10, 2011 Qteros, Inc., ... Bioprocessing (CBP) platform for the lowest-cost production ... engagements across the United States and Europe for members ... Qteros, Senior Vice President, Commercial Development and Engineering, will ...
Cached Biology Technology:Neurocrine Biosciences Reports Fourth Quarter and Year End 2010 Results 2Neurocrine Biosciences Reports Fourth Quarter and Year End 2010 Results 3Neurocrine Biosciences Reports Fourth Quarter and Year End 2010 Results 4Neurocrine Biosciences Reports Fourth Quarter and Year End 2010 Results 5Neurocrine Biosciences Reports Fourth Quarter and Year End 2010 Results 6Neurocrine Biosciences Reports Fourth Quarter and Year End 2010 Results 7ISTO Technologies, Inc. to Present at Canaccord Genuity's Musculoskeletal Conference 2Qteros Management to Present at Notable Alternative Energy Conferences in February 2
(Date:10/29/2014)... At a ceremony held in New York City on ... King, the American Cancer Society Professor of Genome Sciences ... and 2008 Honorary Doctor of Philosophy of Tel Aviv ... in Medical Science. , In addition to her honorary ... Lecturer at the TAU School of Medicine, and for ...
(Date:10/29/2014)... Hebei, China — BGI Tech and Hebei Agricultural University ... Jujube genome. Jujube is the most economically important member ... particularly difficult to sequence due the high level of ... time that a genome in the Rhamnaceae (Buckthorn) family ... in Nature Communications . , Jujube ...
(Date:10/28/2014)... the tragic realities of cancer is that the ... and their effectiveness varies unpredictably from patient to ... to change this reality by rapidly assessing how ... individual,s cancer before chemotherapy begins. , A team ... Assistant Professor Melissa Skala has developed the technique, ...
Breaking Biology News(10 mins):Geneticist and humanitarian: Prof. Mary-Claire King receives Lasker Award 2BGI Tech and Hebei Agricultural University complete the genome sequencing of the jujube tree 2Improving breast cancer chemo by testing patient's tumors in a dish 2Improving breast cancer chemo by testing patient's tumors in a dish 3
... A new computer model of the Gulf of Mexico ... how underwater currents may have primed marine microorganisms to degrade ... of water move over the ruptured well, picking up hydrocarbons. ... over the well, the bacteria have already been activated, are ...
... Species pairs that disappear through hybridization after ... the disturbance is removed, according to a new ... reemergence might happen. The findings, published in ... conservationists and ecosystem managers interested in preserving, or ...
... Foundation for Biodiversity, the Charter Provincial Council of Gipuzkoa and ... be studying the re-stocking of the three eel phases (elver, ... and July, respectively, in three streams of the Oria basin. ... be able to manage the species and thus contribute to ...
Cached Biology News:Gulf currents primed bacteria to degrade oil spill 2Species reemergence after collapse: Possible but different 2A study will enable the survival and growth of the 3 development phases of the European eel 2
... The ProteoExtract™ Protein Precipitation Kit ... up of proteins from aqueous samples. ... by the presence of non-protein impurities ... in the protein sample that interfere ...
... activated carrier proteins to simplify the ... Activated Carrier Proteins are commonly used ... a heterobifunctional cross-linker (Sulfo-SMCC). This activation ... protein. Thus allowing the maleimide-activated ...
... This kit allows for rapid, convenient, ... The simple bind/wash/elute process utilizes a spin ... uses beads for concentration of proteins which ... beads are strong ion exchangers, offering high ...
... optically clear polystyrene with frosted labeling ... for cell counting. 100% integrity tested. ... new product number, created to easily ... no availability yet, please order under ...
Biology Products: